CJ..thanks! This is bigger than most of us can imagine and one can only look at the past for so long and Peregrine is certainly entering a territory they have never been in before. Collaborations with some of the very best cancer researchers, that are seeing the natural benefit of combo treatment with PS Targeting. Dr. Raymond Birge out of Rutgers is clearly proving many people wrong... as well as Dr. Jedd Wolchok and I wonder how many others are looking to get a head start into combo treatment with PS Targeting...
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!